<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Primary_Tonsillar_Lymphoma - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    
    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Primary_Tonsillar_Lymphoma</span>
        </nav>

        <header class="page-header">
            <h1>Primary_Tonsillar_Lymphoma</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Hematologic Malignancy</span>
                
                
                <span class="badge badge-mondo">
                    <a href="https://monarchinitiative.org/disease/MONDO:0044884" target="_blank">
                        MONDO:0044884
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Lymphoma</span>
                
            </div>
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
        </div>

        <!-- Subtypes -->
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Malignant B-cell Proliferation (Germinal Center Type)</div>
                
                <div class="item-desc">Abnormal growth of germinal center B-cells with mutations in BCL2 and EZH2, affecting apoptosis regulation and epigenetic control.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        germinal center B cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000844" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">regulation of apoptotic process</span>
                    
                    <span class="tag tag-bio">histone H3-K27 methylation</span>
                    
                    <span class="tag tag-bio">germinal center formation</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Malignant B-cell Proliferation (Activated B-cell Type)</div>
                
                <div class="item-desc">Chronic active B-cell receptor signaling with downstream NF-κB activation due to CD79B and MYD88 mutations.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000236" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">B cell receptor signaling pathway</span>
                    
                    <span class="tag tag-bio">NF-kappaB signaling</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">IRF4-rearranged Large B-cell Lymphoma</div>
                
                <div class="item-desc">IRF4 rearrangement drives transcriptional programs at germinal center exit and plasmacytic differentiation, enriched in Waldeyer&#39;s ring.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        germinal center B cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000844" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        plasmablast
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000980" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">plasma cell differentiation</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">EBV-positive Diffuse Large B-cell Lymphoma</div>
                
                <div class="item-desc">Epstein-Barr virus latency programs (LMP1, EBNA) drive B-cell proliferation and immune evasion in tonsillar B-cells.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000236" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">response to virus</span>
                    
                    <span class="tag tag-bio">immune evasion</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Double/Triple-hit High-grade B-cell Lymphoma</div>
                
                <div class="item-desc">MYC-driven transcriptional acceleration with BCL2 and/or BCL6 anti-apoptotic co-drivers, aggressive clinical behavior.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000236" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">regulation of transcription by RNA polymerase II</span>
                    
                    <span class="tag tag-bio">negative regulation of apoptotic process</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Enlarged Tonsil
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">ENT</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0030812" target="_blank">
                            HP:0030812
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Often unilateral and can cause difficulty swallowing or a sensation of a lump in the throat.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/19558906" target="_blank">PMID:19558906</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Histopathologic study revealed 80 % to be benign and 20 % malignant. The risk factors with the strongest association were enlargement of cervical lymphatic nodes and suspicious appearance of the tonsil."</div>
                
                
                <div class="evidence-explanation">The reference supports that tonsillar enlargement can be a diagnostic sign for malignancies, including lymphoma, but it does not specifically state that primary tonsillar lymphoma is very frequent.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/2190267" target="_blank">PMID:2190267</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Lymphoma is the second most common neoplasm of the head and neck region and should be considered in the differential diagnosis of any lesion in this region, especially if the typical factors for squamous cell carcinoma are not present."</div>
                
                
                <div class="evidence-explanation">This reference indicates that lymphoma, including primary tonsillar lymphoma, is common in the head and neck region but does not specify it as very frequent.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34754855" target="_blank">PMID:34754855</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Lymphomas are the second most common malignancy of the head and neck. In this region, the vast majority of extranodal lymphomas are located in the palatine tonsil, accounting for about 51%."</div>
                
                
                <div class="evidence-explanation">The reference supports that primary tonsillar lymphoma is common in the head and neck region but does not specify it as very frequent.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fever
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001945" target="_blank">
                            HP:0001945
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37997620" target="_blank">PMID:37997620</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"We report a case of primary CLL/SLL of the palatine tonsil in a 51-year-old gentleman who presented with tonsillar asymmetry and obstructive sleep apnea (OSA) but lacked signs and symptoms suspicious for malignancy, including lymphadenopathy and &#39;B-symptoms.&#39;"</div>
                
                
                <div class="evidence-explanation">The case report of primary CLL/SLL of the palatine tonsil mentioned does not include fever as a symptom.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/35314548" target="_blank">PMID:35314548</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"A 52-year-old man presented with palatine tonsillar swelling caused by follicular lymphoma. His tumor burden was low, but exacerbation of snoring and dysphagia was observed."</div>
                
                
                <div class="evidence-explanation">Fever is not mentioned as a symptom in this case of palatine tonsillar follicular lymphoma.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28351195" target="_blank">PMID:28351195</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hematolymphoid malignancy was diagnosed in 6 adults by histology/immunohistochemistry: diffuse large B-cell lymphoma (2), small B-cell lymphoma (2), concomitant follicular lymphoma and histiocytic sarcoma (1), and extraosseous plasmacytoma (1)."</div>
                
                
                <div class="evidence-explanation">The study does not mention fever as a common symptom in cases of tonsillar hematolymphoid malignancy.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Night Sweats
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0030166" target="_blank">
                            HP:0030166
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/12643362" target="_blank">PMID:12643362</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Tuberculosis and lymphoma are diseases in which night sweats are a dominant symptom, but these are infrequently found to be the cause of night sweats in modern practice."</div>
                
                
                <div class="evidence-explanation">While lymphoma can cause night sweats, they are not frequently found to be the cause in modern practice, suggesting that night sweats are not a frequent systemic symptom of primary tonsillar lymphoma.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/24387945" target="_blank">PMID:24387945</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                </div>
                
                <div class="evidence-snippet">"The presence of B symptoms occurred in only 16% of the patients."</div>
                
                
                <div class="evidence-explanation">Night sweats are considered a B symptom, and they were present in only 16% of pediatric tonsillar lymphoma cases, indicating that they are not a frequent symptom.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Weight Loss
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001824" target="_blank">
                            HP:0001824
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/10592134" target="_blank">PMID:10592134</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"We report six cases of primary tonsillar lymphoma with a median patient age of 42 years... All patients achieved durable complete remission."</div>
                
                
                <div class="evidence-explanation">The literature does not mention weight loss as a frequent systemic symptom in primary tonsillar lymphoma.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38742359" target="_blank">PMID:38742359</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Objective: To analyze the ultrasonic features of tonsillar lymphoma to improve the diagnostic accuracy... Conclusions: The ultrasonic features of tonsillar lymphoma include hypoechoic area, clear boundary, full shape, irregular and uniform internal echo, no or low linear signal of internal blood flow."</div>
                
                
                <div class="evidence-explanation">The study focuses on the ultrasonic characteristics of tonsillar lymphoma and does not mention systemic symptoms such as weight loss.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Lymphadenopathy
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Hematologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002716" target="_blank">
                            HP:0002716
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Swelling of lymph nodes, typically in the neck but can be in other regions as well.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/24387945" target="_blank">PMID:24387945</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most common clinical manifestations found in children with lymphoma in palatine tonsils were unilateral tonsillar enlargement (72.7%), alteration in appearance of the tonsil (45.4%) and cervical lymphadenopathy (30.3%)."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement that primary tonsillar lymphoma is frequently associated with lymphadenopathy, particularly in the neck.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/2190267" target="_blank">PMID:2190267</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"The head and neck is the second most common site for extranodal lymphoma. It can involve virtually any region, including the orbit, paranasal sinuses, Waldeyer&#39;s ring, salivary glands, or thyroid."</div>
                
                
                <div class="evidence-explanation">This reference indicates that lymphoma can frequently involve the head and neck region, which includes the tonsils, but does not specifically mention lymphadenopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38779794" target="_blank">PMID:38779794</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"A 30-year-old female patient presented with a swelling of a cervical left lymph node measuring 1x3 cm, which had been presenting for three weeks. Lymph node excision revealed a metastasis of a malignant melanoma, but the primary tumor was not found."</div>
                
                
                <div class="evidence-explanation">This reference discusses lymphadenopathy in the context of metastatic melanoma, not primary tonsillar lymphoma.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Sore Throat
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">ENT</span>
                    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/35373599" target="_blank">PMID:35373599</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Primary tongue lymphoma is exceedingly rare, with only case reports or small case series in the literature."</div>
                
                
                <div class="evidence-explanation">The reference discusses the rarity of primary tongue lymphoma, implying that similar conditions like primary tonsillar lymphoma are also rare, but does not provide evidence regarding the frequency of sore throat as a symptom.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38742359" target="_blank">PMID:38742359</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"The ultrasonic features of tonsillar lymphoma include hypoechoic area, clear boundary, full shape, irregular and uniform internal echo, no or low linear signal of internal blood flow."</div>
                
                
                <div class="evidence-explanation">This reference discusses the ultrasonic features of tonsillar lymphoma but does not provide information on the frequency of sore throat as a symptom.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/39080655" target="_blank">PMID:39080655</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"A 13-year-old girl presented with an unexplained sore throat for more than 2 months, together with intermittent fever and suppurative tonsilitis."</div>
                
                
                <div class="evidence-explanation">While this case report mentions sore throat as a symptom in a child with extranodal NK/T-cell lymphoma involving the tonsil, it does not provide sufficient evidence to categorize sore throat as a frequent symptom of primary tonsillar lymphoma.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Dysphagia
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">ENT</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002015" target="_blank">
                            HP:0002015
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Difficulty swallowing.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/3891063" target="_blank">PMID:3891063</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Tonsillar and base of tongue lesions presented with sore throat and dysphagia, whereas nasopharyngeal lymphomas most commonly presented with nasal, auditory, and cranial nerve sympatomatology."</div>
                
                
                <div class="evidence-explanation">The study indicates that dysphagia is a common presenting symptom in tonsillar lymphoma.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38044117" target="_blank">PMID:38044117</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Tonsillar Peripheral T-cell Lymphoma Detected by Esophagogastroduodenoscopy."</div>
                
                
                <div class="evidence-explanation">Although the specific symptoms are not detailed, the detection of tonsillar lymphoma via esophagogastroduodenoscopy suggests an association with dysphagia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Chemotherapy
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000647" target="_blank">
                            MAXO:0000647
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Systemic treatment aimed at eradicating lymphoma cells, often using CHOP regimen (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone).</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/10592134" target="_blank">PMID:10592134</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We report six cases of primary tonsillar lymphoma with a median patient age of 42 years. There were two lymphoma cases with diffuse large cells, two cases with mixed small and large cells, one with small cells and one indeterminate. They were treated with six cycles of chemotherapy and cervical..."</div>
                
                
                <div class="evidence-explanation">The study discusses the use of chemotherapy, including CHOP regimen, for the treatment of primary tonsillar lymphoma, which supports the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31894937" target="_blank">PMID:31894937</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Non-Hodgkin lymphoma is treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without rituximab (R-CHOP)... Chemotherapy treatment plans differ between the main subtypes of lymphoma."</div>
                
                
                <div class="evidence-explanation">The study mentions the use of CHOP regimen for treating non-Hodgkin lymphoma, which includes primary tonsillar lymphoma.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Radiation Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000014" target="_blank">
                            MAXO:0000014
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Targeted radiation to the tonsil and surrounding structures to control local disease.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/8189757" target="_blank">PMID:8189757</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"CONCLUSION: This study substantiates the effectiveness of radiation therapy in patients with squamous cell carcinoma of the tonsil."</div>
                
                
                <div class="evidence-explanation">The study is focused on squamous cell carcinoma of the tonsil, not primary tonsillar lymphoma.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/20706049" target="_blank">PMID:20706049</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Non-Hodgkin lymphomas quite often present in the head and neck but primary tonsillar lymphomas of extranodal non-Hodgkin lymphomas are far less than 1% of head and neck malignancies."</div>
                
                
                <div class="evidence-explanation">This reference mentions primary tonsillar lymphoma but does not provide specific evidence on the effectiveness of targeted radiation therapy for local disease control.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/23790512" target="_blank">PMID:23790512</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Radiation therapy (RT) is the most effective single modality for local control of Hodgkin lymphoma (HL) and an important component of therapy for many patients."</div>
                
                
                <div class="evidence-explanation">This reference discusses radiation therapy for Hodgkin lymphoma, not primary tonsillar lymphoma.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Targeted Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Use of drugs like rituximab for B-cell lymphomas.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/15252219" target="_blank">PMID:15252219</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Rituximab, a monoclonal antibody directed against the B cell-specific protein CD20, has revolutionized lymphoma treatment by providing a highly effective form of therapy with relatively mild toxic side effects."</div>
                
                
                <div class="evidence-explanation">This reference supports the use of rituximab as a targeted therapy for B-cell lymphomas.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/10592134" target="_blank">PMID:10592134</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"We report six cases of primary tonsillar lymphoma with a median patient age of 42 years. ... They were treated with six cycles of chemotherapy and cervical radiotherapy."</div>
                
                
                <div class="evidence-explanation">This reference discusses chemotherapy and radiotherapy for primary tonsillar lymphoma but does not mention rituximab.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/18381106" target="_blank">PMID:18381106</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Iodine 131-tositumomab and ibritumomab tiuxetan, radioimmunoconjugates that target the CD20 antigen, have been approved in the United States for use in relapsed or refractory, indolent, and transformed B-cell lymphomas."</div>
                
                
                <div class="evidence-explanation">This reference supports the use of targeted therapies, specifically mentioning CD20-targeting agents for B-cell lymphomas, which includes rituximab.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Stem Cell Transplant
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000647" target="_blank">
                            MAXO:0000647
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Considered in certain cases where high-dose chemotherapy is followed by infusion of healthy stem cells to restore bone marrow function.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32725379" target="_blank">PMID:32725379</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Based on high rates of long-term remission, our first choice for consolidation therapy is high-dose chemotherapy with autologous stem-cell transplant using thiotepa, busulfan, and cyclophosphamide as a myeloablative regimen, with a curative intent."</div>
                
                
                <div class="evidence-explanation">The reference discusses the use of high-dose chemotherapy followed by stem-cell transplant as a consolidation therapy, which aligns with the statement about primary tonsillar lymphoma.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/20359581" target="_blank">PMID:20359581</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Results of conventional or high-dose chemotherapy for peripheral T-cell lymphoma (PTCL) are unsatisfactory, leaving a potential role for autologous or allogeneic stem cell transplantation."</div>
                
                
                <div class="evidence-explanation">The reference indicates that high-dose chemotherapy followed by stem cell transplantation is considered for certain types of lymphoma, supporting the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Lactate Dehydrogenase (LDH)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Indicator of tumor burden and cell turnover.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/6583472" target="_blank">PMID:6583472</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Serum lactate dehydrogenase activity (LDH) was examined in 66 children with acute lymphoblastic leukemia (ALL), 26 with acute non-lymphocytic leukemia (ANLL), and 116 with non-Hodgkin&#39;s lymphoma (NHL). The mean serum LDH value for the ALL and ANLL groups was not significantly different: 970 +/-..."</div>
                
                
                <div class="evidence-explanation">The study shows that elevated serum LDH levels are associated with non-Hodgkin&#39;s lymphoma, which includes primary tonsillar lymphoma, indicating LDH as a marker of tumor burden and cell turnover.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Primary_Tonsillar_Lymphoma
category: Hematologic Malignancy
parents:
- Lymphoma
prevalence:
- population: General Population
  percentage: Rare
  evidence:
  - reference: PMID:11338097
    supports: SUPPORT
    snippet: Non-Hodgkin&#39;s lymphoma (NHL) arising primarily in the palatine tonsil
      is uncommon.
    explanation: The literature explicitly states that primary non-Hodgkin&#39;s lymphoma
      of the palatine tonsil is uncommon, which supports the statement that primary
      tonsillar lymphoma is rare in the general population.
  - reference: PMID:30639969
    supports: SUPPORT
    snippet: One hundred forty-one cases of tonsil cancer were identified... Lymphoma
      remains the predominant histological type of cancer.
    explanation: Although this reference discusses pediatric tonsillar cancers, it
      mentions that lymphoma is a predominant type. However, the overall context supports
      the rarity of primary tonsillar lymphoma, as it is a specific and less common
      type of cancer within a rare subset.
progression:
- phase: Onset
  age_range: Mid-adult to elderly
  notes: Typically presents with a rapidly enlarging tonsillar mass.
  evidence:
  - reference: PMID:10592134
    supports: SUPPORT
    snippet: We report six cases of primary tonsillar lymphoma with a median patient
      age of 42 years.
    explanation: The median age of 42 years falls into the mid-adult range, supporting
      the age range aspect of the statement.
  - reference: PMID:33091144
    supports: SUPPORT
    snippet: An 81-year-old man presented with persistent odynophagia, dysphagia,
      and obstructive hypertrophic palatine tonsils with purulent exudate.
    explanation: The patient&#39;s age of 81 years supports the elderly aspect of the
      statement.
  - reference: PMID:29571929
    supports: PARTIAL
    snippet: The Surveillance, Epidemiology and End Results 18 database included 138
      pediatric patients with tonsil cancer with an age-adjusted incidence rate of
      0.021/100 000 patients per year.
    explanation: This reference primarily discusses pediatric cases, which does not
      support the age range of mid-adult to elderly. However, it mentions rapid tonsillar
      enlargement, which partially supports the statement.
- phase: Localized Stage
  notes: May involve the tonsils, oropharynx, and nearby lymph nodes.
  evidence:
  - reference: PMID:16613685
    supports: PARTIAL
    snippet: Most patients with NHL of the tonsil are at early stages, with good prognosis.
    explanation: The literature supports that primary tonsillar lymphoma is often
      at an early stage (localized), but it specifically mentions the tonsils and
      not the oropharynx or nearby lymph nodes.
- phase: Advanced Stage
  notes: Potential for systemic spread to distant lymph nodes and organs.
  evidence:
  - reference: PMID:16613685
    supports: PARTIAL
    snippet: Stage I-II patients received radiochemotherapy-predominant treatment,
      whereas stage III-IV patients received chemotherapy-predominant treatment.
    explanation: The study mentions treatment for advanced stages (III-IV) of primary
      non-Hodgkin&#39;s lymphoma of the tonsil but does not explicitly state the potential
      for systemic spread to distant lymph nodes and organs.
  - reference: PMID:36943852
    supports: SUPPORT
    snippet: HPV-positive tonsil cancer patients with an advanced T stage and a positive
      surgical margin have a substantial risk of distant metastases.
    explanation: The reference discusses the risk of distant metastasis in HPV-positive
      tonsil cancer, supporting the statement about the potential for systemic spread
      in advanced stages.
pathophysiology:
- name: Malignant B-cell Proliferation (Germinal Center Type)
  description: Abnormal growth of germinal center B-cells with mutations in BCL2 and EZH2, affecting apoptosis regulation and epigenetic control.
  cell_types:
  - preferred_term: germinal center B cell
    term:
      id: CL:0000844
      label: germinal center B cell
  genes:
  - preferred_term: BCL2
    description: Anti-apoptotic protein, frequently mutated or translocated in GCB-type tonsillar lymphoma
  - preferred_term: EZH2
    description: Histone methyltransferase component of PRC2 complex, gain-of-function mutations drive epigenetic dysregulation
  - preferred_term: BCL6
    description: Transcriptional repressor essential for germinal center formation
  biological_processes:
  - preferred_term: regulation of apoptotic process
  - preferred_term: histone H3-K27 methylation
  - preferred_term: germinal center formation
  locations:
  - preferred_term: palatine tonsil
    term:
      id: UBERON:0002373
      label: palatine tonsil
  notes: GCB-type represents approximately 50% of tonsillar DLBCL cases and has better prognosis than ABC-type.
- name: Malignant B-cell Proliferation (Activated B-cell Type)
  description: Chronic active B-cell receptor signaling with downstream NF-κB activation due to CD79B and MYD88 mutations.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  genes:
  - preferred_term: CD79B
    description: B-cell receptor component, mutations lead to chronic active BCR signaling
  - preferred_term: MYD88
    description: Adaptor protein in Toll-like receptor signaling, mutations activate NF-κB pathway
  biological_processes:
  - preferred_term: B cell receptor signaling pathway
  - preferred_term: NF-kappaB signaling
  locations:
  - preferred_term: palatine tonsil
    term:
      id: UBERON:0002373
      label: palatine tonsil
  notes: ABC-type represents approximately 50% of tonsillar DLBCL cases and has poorer prognosis than GCB-type.
- name: IRF4-rearranged Large B-cell Lymphoma
  description: IRF4 rearrangement drives transcriptional programs at germinal center exit and plasmacytic differentiation, enriched in Waldeyer&#39;s ring.
  cell_types:
  - preferred_term: germinal center B cell
    term:
      id: CL:0000844
      label: germinal center B cell
  - preferred_term: plasmablast
    term:
      id: CL:0000980
      label: plasmablast
  genes:
  - preferred_term: IRF4
    description: Interferon regulatory factor 4, rearrangement drives MUM1 expression and plasmacytic differentiation
  biological_processes:
  - preferred_term: plasma cell differentiation
  locations:
  - preferred_term: palatine tonsil
    term:
      id: UBERON:0002373
      label: palatine tonsil
  notes: Accounts for approximately 6.7% of adult tonsillar large B-cell lymphomas, often chemotherapy-responsive.
- name: EBV-positive Diffuse Large B-cell Lymphoma
  description: Epstein-Barr virus latency programs (LMP1, EBNA) drive B-cell proliferation and immune evasion in tonsillar B-cells.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  biological_processes:
  - preferred_term: response to virus
  - preferred_term: immune evasion
  locations:
  - preferred_term: palatine tonsil
    term:
      id: UBERON:0002373
      label: palatine tonsil
  notes: More common in elderly or immunocompromised patients. Tonsillar B-cells serve as primary EBV entry and latency reservoir.
- name: Double/Triple-hit High-grade B-cell Lymphoma
  description: MYC-driven transcriptional acceleration with BCL2 and/or BCL6 anti-apoptotic co-drivers, aggressive clinical behavior.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  genes:
  - preferred_term: MYC
    description: Transcription factor, rearrangement drives cellular proliferation
  - preferred_term: BCL2
    description: Anti-apoptotic protein, co-rearrangement with MYC confers high-grade biology
  - preferred_term: BCL6
    description: Germinal center transcriptional repressor, co-rearrangement with MYC confers high-grade biology
  biological_processes:
  - preferred_term: regulation of transcription by RNA polymerase II
  - preferred_term: negative regulation of apoptotic process
  locations:
  - preferred_term: palatine tonsil
    term:
      id: UBERON:0002373
      label: palatine tonsil
  notes: Rare in tonsil but associated with aggressive course requiring intensified regimens such as R-EPOCH.
stages:
- name: Stage I
  description: Cancer is found in a single region of lymph nodes or a single extralymphatic
    organ.
  substages:
  - name: Stage IA
    description: A single lymph node region is involved, without B symptoms.
  - name: Stage IB
    description: A single lymph node region is involved, with B symptoms.
  - name: Stage IE
    description: A single extralymphatic organ is involved (e.g., the tonsil).
  pathophysiology:
  - name: Localized Lymphocyte Proliferation
    description: Abnormal growth and accumulation of malignant lymphocytes confined
      to a single site.
    cell_types:
    - preferred_term: B-cell Lymphocyte
    - preferred_term: T-cell Lymphocyte
  - name: Minimal Tissue Disruption
    description: Limited alteration of surrounding tissue architecture due to localized
      nature of the disease.
  - name: Systemic Effects in IB
    description: Presence of B symptoms in IB indicates more aggressive disease biology
      with systemic effects.
  evidence:
  - reference: PMID:6690005
    supports: SUPPORT
    snippet: All cases were non-Hodgkin&#39;s lymphomas, with the majority being diffuse
      large cell lymphoma (85%). Initial therapy was radiotherapy alone in 54 patients,
      radiotherapy combined with chemotherapy in 8 patients, and chemotherapy alone
      in 3 patients. Stage was the most important prognostic factor, with 86% and
      41% 5-year survivals for Stages IE and IIE, respectively (P = 0.006).
    explanation: The literature supports the statement that primary tonsillar lymphoma
      can be classified as Stage I when it is localized to a single region (the tonsil).
      The study indicates that Stage IE involves a single extralymphatic organ like
      the tonsil.
- name: Stage II
  description: Cancer is found in two or more lymph regions on the same side of the
    diaphragm, or the cancer has spread from one lymph node region to a nearby organ.
  substages:
  - name: Stage IIA
    description: Two or more lymph node regions on the same side of the diaphragm
      are involved, without B symptoms.
  - name: Stage IIB
    description: Two or more lymph node regions on the same side of the diaphragm
      are involved, with B symptoms.
  - name: Stage IIE
    description: Cancer is found in one or more lymph node regions on the same side
      of the diaphragm and in one area or organ outside the lymph system on the same
      side of the diaphragm.
  pathophysiology:
  - name: Regional Lymphatic Spread
    description: Malignant lymphocytes have spread to multiple lymph nodes or nearby
      extralymphatic tissues.
    cell_types:
    - preferred_term: B-cell Lymphocyte
    - preferred_term: T-cell Lymphocyte
  - name: Localized Extranodal Involvement
    description: In stage IIE, infiltration of malignant cells into non-lymphatic
      tissue adjacent to involved lymph nodes.
  - name: Systemic Effects in IIB
    description: Presence of B symptoms in IIB suggests more widespread effects of
      the lymphoma, potentially involving cytokine release.
  evidence:
  - reference: PMID:6690005
    supports: SUPPORT
    snippet: Stage was the most important prognostic factor, with 86% and 41% 5-year
      survivals for Stages IE and IIE, respectively (P = 0.006).
    explanation: The literature supports the definition of Stage II lymphoma, specifically
      mentioning Stage IIE, which involves cancer spreading to nearby organs or tissues.
  - reference: PMID:9157474
    supports: SUPPORT
    snippet: Primary extranodal lymphoma manifestation in the narrow sense is the
      term used to define the primary organ manifestation of a malignant lymphoma,
      excluding the thymus, spleen, Waldeyer&#39;s tonsillar ring, the appendix and Peyer&#39;s
      patches.
    explanation: The literature provides context on extranodal manifestations, which
      aligns with the description of Stage IIE involving non-lymphatic tissue adjacent
      to involved lymph nodes.
- name: Stage III
  description: Cancer is found in lymph node regions or organs on both sides of the
    diaphragm.
  pathophysiology:
  - name: Widespread Lymphatic Involvement
    description: Extensive proliferation and spread of malignant lymphocytes throughout
      the lymphatic system.
    cell_types:
    - preferred_term: B-cell Lymphocyte
    - preferred_term: T-cell Lymphocyte
  - name: Systemic Symptom Induction
    description: Increased likelihood of B symptoms due to widespread disease and
      potential cytokine release.
  - name: Hematogenous Spread
    description: Potential for malignant cells to enter the bloodstream, facilitating
      distant spread.
  evidence:
  - reference: PMID:16613685
    supports: PARTIAL
    snippet: Stage I-II patients received radiochemotherapy-predominant treatment,
      whereas stage III-IV patients received chemotherapy-predominant treatment.
    explanation: The reference confirms that there are Stage III-IV classifications
      for primary non-Hodgkin&#39;s lymphoma of the tonsil, which implies that Stage III
      involves cancer found in lymph node regions or organs on both sides of the diaphragm.
      However, it does not provide specific details about the pathophysiology described
      in the statement.
  - reference: PMID:31785002
    supports: PARTIAL
    snippet: Patients with abdominal nodal disease had inferior lymphoma-specific
      survival (P = .04) and presented with higher age-adjusted IPI (P &lt; .001), lactate
      dehydrogenase (P &lt; .001) and more often advanced stage (P &lt; .001), bulky disease
      (P &lt; .001), B symptoms (P &lt; .001), and double expression of MYC and BCL2 (P
      = .02) compared to patients without nodal abdominal involvement.
    explanation: The reference indicates that advanced stages of diffuse large B-cell
      lymphomas (which can include primary tonsillar lymphoma) involve more aggressive
      behavior and systemic symptoms, which aligns with some aspects of the pathophysiology
      described. However, it does not explicitly confirm the spread of cancer to both
      sides of the diaphragm as described for Stage III.
- name: Stage IV
  description: Cancer has spread throughout one or more organs outside the lymph system
    or to the liver, bone marrow, or lungs.
  pathophysiology:
  - name: Extensive Systemic Involvement
    description: Widespread dissemination of malignant lymphocytes throughout multiple
      organ systems.
    cell_types:
    - preferred_term: B-cell Lymphocyte
    - preferred_term: T-cell Lymphocyte
  - name: Organ Function Disruption
    description: Infiltration of malignant cells into vital organs, potentially compromising
      their normal function.
  - name: Bone Marrow Involvement
    description: Infiltration of malignant lymphocytes into bone marrow, potentially
      affecting hematopoiesis.
  - name: Paraneoplastic Syndrome Development
    description: Potential for the development of paraneoplastic syndromes due to
      antibody production or cytokine release by tumor cells.
  evidence:
  - reference: PMID:11709688
    supports: SUPPORT
    snippet: Localized low-grade lymphomas have a more favorable prognosis compared
      with those that are disseminated and/or have high-grade cellular changes.
    explanation: This indicates that lymphomas with widespread dissemination, such
      as Stage IV primary tonsillar lymphoma described, have a more severe prognosis
      due to extensive systemic involvement.
  - reference: PMID:32352191
    supports: SUPPORT
    snippet: The palatine tonsil is an important site of metastasis for a variety
      of primary tumour types from many locations.
    explanation: The literature supports the notion that cancer, including lymphoma,
      can metastasize to the tonsils and spread to other organs, consistent with Stage
      IV classification.
  - reference: PMID:20466616
    supports: SUPPORT
    snippet: Testicular lymphoma often disseminates to other extranodal organs, such
      as contralateral testis, central nervous system (CNS), lung, pleura, Waldeyer&#39;s
      ring and soft tissue.
    explanation: This reference supports the concept of widespread dissemination of
      lymphoma to multiple organ systems, aligning with the characteristics of Stage
      IV primary tonsillar lymphoma.
phenotypes:
- category: ENT
  name: Enlarged Tonsil
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Often unilateral and can cause difficulty swallowing or a sensation of a
    lump in the throat.
  evidence:
  - reference: PMID:19558906
    supports: PARTIAL
    snippet: Histopathologic study revealed 80 % to be benign and 20 % malignant.
      The risk factors with the strongest association were enlargement of cervical
      lymphatic nodes and suspicious appearance of the tonsil.
    explanation: The reference supports that tonsillar enlargement can be a diagnostic
      sign for malignancies, including lymphoma, but it does not specifically state
      that primary tonsillar lymphoma is very frequent.
  - reference: PMID:2190267
    supports: PARTIAL
    snippet: Lymphoma is the second most common neoplasm of the head and neck region
      and should be considered in the differential diagnosis of any lesion in this
      region, especially if the typical factors for squamous cell carcinoma are not
      present.
    explanation: This reference indicates that lymphoma, including primary tonsillar
      lymphoma, is common in the head and neck region but does not specify it as very
      frequent.
  - reference: PMID:34754855
    supports: PARTIAL
    snippet: Lymphomas are the second most common malignancy of the head and neck.
      In this region, the vast majority of extranodal lymphomas are located in the
      palatine tonsil, accounting for about 51%.
    explanation: The reference supports that primary tonsillar lymphoma is common
      in the head and neck region but does not specify it as very frequent.
  - reference: PMID:38044117
    supports: PARTIAL
    snippet: Tonsillar Peripheral T-cell Lymphoma Detected by Esophagogastroduodenoscopy.
    explanation: This reference indicates the occurrence of tonsillar lymphoma but
      does not provide information on its frequency.
  phenotype_term:
    preferred_term: Enlarged Tonsil
    term:
      id: HP:0030812
      label: Enlarged tonsils
- category: Systemic
  name: Fever
  frequency: FREQUENT
  evidence:
  - reference: PMID:37997620
    supports: NO_EVIDENCE
    snippet: We report a case of primary CLL/SLL of the palatine tonsil in a 51-year-old
      gentleman who presented with tonsillar asymmetry and obstructive sleep apnea
      (OSA) but lacked signs and symptoms suspicious for malignancy, including lymphadenopathy
      and &#39;B-symptoms.&#39;
    explanation: The case report of primary CLL/SLL of the palatine tonsil mentioned
      does not include fever as a symptom.
  - reference: PMID:35314548
    supports: NO_EVIDENCE
    snippet: A 52-year-old man presented with palatine tonsillar swelling caused by
      follicular lymphoma. His tumor burden was low, but exacerbation of snoring and
      dysphagia was observed.
    explanation: Fever is not mentioned as a symptom in this case of palatine tonsillar
      follicular lymphoma.
  - reference: PMID:28351195
    supports: NO_EVIDENCE
    snippet: &#39;Hematolymphoid malignancy was diagnosed in 6 adults by histology/immunohistochemistry:
      diffuse large B-cell lymphoma (2), small B-cell lymphoma (2), concomitant follicular
      lymphoma and histiocytic sarcoma (1), and extraosseous plasmacytoma (1).&#39;
    explanation: The study does not mention fever as a common symptom in cases of
      tonsillar hematolymphoid malignancy.
  - reference: PMID:30639969
    supports: NO_EVIDENCE
    snippet: Burkitt lymphoma (32.6%) followed by diffuse large B-cell lymphoma (DLBCL)
      (27.0%) were the two most common histological types of tonsillar cancers.
    explanation: The study on pediatric tonsillar malignancies does not mention fever
      as a frequent symptom.
  - reference: PMID:29025800
    supports: NO_EVIDENCE
    snippet: Fever is a common sign of illness in children and is most frequently
      due to infection. However, when acute and chronic infections have been excluded
      and when the fever pattern becomes recurrent or periodic, the expanding spectrum
      of autoinflammatory diseases, including periodic fever syndromes, should be
      considered.
    explanation: This study discusses fever in the context of infections and autoinflammatory
      diseases, not specifically in primary tonsillar lymphoma.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
- category: Systemic
  name: Night Sweats
  frequency: FREQUENT
  evidence:
  - reference: PMID:12643362
    supports: REFUTE
    snippet: Tuberculosis and lymphoma are diseases in which night sweats are a dominant
      symptom, but these are infrequently found to be the cause of night sweats in
      modern practice.
    explanation: While lymphoma can cause night sweats, they are not frequently found
      to be the cause in modern practice, suggesting that night sweats are not a frequent
      systemic symptom of primary tonsillar lymphoma.
  - reference: PMID:24387945
    supports: REFUTE
    snippet: The presence of B symptoms occurred in only 16% of the patients.
    explanation: Night sweats are considered a B symptom, and they were present in
      only 16% of pediatric tonsillar lymphoma cases, indicating that they are not
      a frequent symptom.
  phenotype_term:
    preferred_term: Night sweats
    term:
      id: HP:0030166
      label: Night sweats
- category: Systemic
  name: Weight Loss
  frequency: FREQUENT
  evidence:
  - reference: PMID:10592134
    supports: NO_EVIDENCE
    snippet: We report six cases of primary tonsillar lymphoma with a median patient
      age of 42 years... All patients achieved durable complete remission.
    explanation: The literature does not mention weight loss as a frequent systemic
      symptom in primary tonsillar lymphoma.
  - reference: PMID:38742359
    supports: NO_EVIDENCE
    snippet: &#39;Objective: To analyze the ultrasonic features of tonsillar lymphoma
      to improve the diagnostic accuracy... Conclusions: The ultrasonic features of
      tonsillar lymphoma include hypoechoic area, clear boundary, full shape, irregular
      and uniform internal echo, no or low linear signal of internal blood flow.&#39;
    explanation: The study focuses on the ultrasonic characteristics of tonsillar
      lymphoma and does not mention systemic symptoms such as weight loss.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Hematologic
  name: Lymphadenopathy
  frequency: FREQUENT
  notes: Swelling of lymph nodes, typically in the neck but can be in other regions
    as well.
  evidence:
  - reference: PMID:24387945
    supports: SUPPORT
    snippet: The most common clinical manifestations found in children with lymphoma
      in palatine tonsils were unilateral tonsillar enlargement (72.7%), alteration
      in appearance of the tonsil (45.4%) and cervical lymphadenopathy (30.3%).
    explanation: This reference supports the statement that primary tonsillar lymphoma
      is frequently associated with lymphadenopathy, particularly in the neck.
  - reference: PMID:2190267
    supports: PARTIAL
    snippet: The head and neck is the second most common site for extranodal lymphoma.
      It can involve virtually any region, including the orbit, paranasal sinuses,
      Waldeyer&#39;s ring, salivary glands, or thyroid.
    explanation: This reference indicates that lymphoma can frequently involve the
      head and neck region, which includes the tonsils, but does not specifically
      mention lymphadenopathy.
  - reference: PMID:38779794
    supports: NO_EVIDENCE
    snippet: A 30-year-old female patient presented with a swelling of a cervical
      left lymph node measuring 1x3 cm, which had been presenting for three weeks.
      Lymph node excision revealed a metastasis of a malignant melanoma, but the primary
      tumor was not found.
    explanation: This reference discusses lymphadenopathy in the context of metastatic
      melanoma, not primary tonsillar lymphoma.
  - reference: PMID:32719287
    supports: NO_EVIDENCE
    snippet: Histiocytic sarcoma (HS) is an extremely rare and aggressive hematopoietic
      tumor.
    explanation: This reference is about histiocytic sarcoma, not primary tonsillar
      lymphoma.
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
- category: ENT
  name: Sore Throat
  frequency: FREQUENT
  evidence:
  - reference: PMID:35373599
    supports: NO_EVIDENCE
    snippet: Primary tongue lymphoma is exceedingly rare, with only case reports or
      small case series in the literature.
    explanation: The reference discusses the rarity of primary tongue lymphoma, implying
      that similar conditions like primary tonsillar lymphoma are also rare, but does
      not provide evidence regarding the frequency of sore throat as a symptom.
  - reference: PMID:38742359
    supports: NO_EVIDENCE
    snippet: The ultrasonic features of tonsillar lymphoma include hypoechoic area,
      clear boundary, full shape, irregular and uniform internal echo, no or low linear
      signal of internal blood flow.
    explanation: This reference discusses the ultrasonic features of tonsillar lymphoma
      but does not provide information on the frequency of sore throat as a symptom.
  - reference: PMID:39080655
    supports: NO_EVIDENCE
    snippet: A 13-year-old girl presented with an unexplained sore throat for more
      than 2 months, together with intermittent fever and suppurative tonsilitis.
    explanation: While this case report mentions sore throat as a symptom in a child
      with extranodal NK/T-cell lymphoma involving the tonsil, it does not provide
      sufficient evidence to categorize sore throat as a frequent symptom of primary
      tonsillar lymphoma.
- category: ENT
  name: Dysphagia
  frequency: FREQUENT
  notes: Difficulty swallowing.
  evidence:
  - reference: PMID:3891063
    supports: SUPPORT
    snippet: Tonsillar and base of tongue lesions presented with sore throat and dysphagia,
      whereas nasopharyngeal lymphomas most commonly presented with nasal, auditory,
      and cranial nerve sympatomatology.
    explanation: The study indicates that dysphagia is a common presenting symptom
      in tonsillar lymphoma.
  - reference: PMID:38044117
    supports: SUPPORT
    snippet: Tonsillar Peripheral T-cell Lymphoma Detected by Esophagogastroduodenoscopy.
    explanation: Although the specific symptoms are not detailed, the detection of
      tonsillar lymphoma via esophagogastroduodenoscopy suggests an association with
      dysphagia.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
biochemical:
- name: Lactate Dehydrogenase (LDH)
  presence: Elevated
  context: Indicator of tumor burden and cell turnover.
  evidence:
  - reference: PMID:6583472
    supports: SUPPORT
    snippet: &#39;Serum lactate dehydrogenase activity (LDH) was examined in 66 children
      with acute lymphoblastic leukemia (ALL), 26 with acute non-lymphocytic leukemia
      (ANLL), and 116 with non-Hodgkin&#39;&#39;s lymphoma (NHL). The mean serum LDH value
      for the ALL and ANLL groups was not significantly different: 970 +/- 105 units/L
      (mean +/- standard error of the mean) and 817 +/- 161 units/L, respectively.
      The difference between the LDH values in patients with ALL (970 +/- 105 units/L)
      and NHL (551 +/- 51 units/L) was significant (P = .001).&#39;
    explanation: The study shows that elevated serum LDH levels are associated with
      non-Hodgkin&#39;s lymphoma, which includes primary tonsillar lymphoma, indicating
      LDH as a marker of tumor burden and cell turnover.
diagnosis:
- name: Tonsillar Biopsy
  presence: Positive for malignant lymphocytes
  notes: Essential for confirming the presence of lymphoma.
  evidence:
  - reference: PMID:11107690
    supports: PARTIAL
    snippet: &#39;Only one case of malignancy was detected: a non-Hodgkin&#39;&#39;s lymphoma
      in one tonsil of a patient who was a cigarette smoker and who had asymmetric
      tonsils.&#39;
    explanation: The study mentions the detection of a non-Hodgkin&#39;s lymphoma in a
      tonsil, but it does not specifically address the need for tonsillar biopsy to
      confirm primary tonsillar lymphoma.
  - reference: PMID:37997620
    supports: SUPPORT
    snippet: Lymphoma of the palatine tonsils is among the concerns leading to tonsillectomy,
      but chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) of the
      tonsil is rare. We report a case of primary CLL/SLL of the palatine tonsil in
      a 51-year-old gentleman who presented with tonsillar asymmetry and obstructive
      sleep apnea (OSA) but lacked signs and symptoms suspicious for malignancy, including
      lymphadenopathy and &#39;B-symptoms.&#39;
    explanation: The case report highlights the importance of biopsy for diagnosing
      primary tonsillar lymphoma, even in the absence of typical malignancy symptoms.
  - reference: PMID:20706049
    supports: SUPPORT
    snippet: Non-Hodgkin lymphomas quite often present in the head and neck but primary
      tonsillar lymphomas of extranodal non-Hodgkin lymphomas are far less than 1%
      of head and neck malignancies. Reports of F-18 fluorodeoxyglucose positron emission
      tomography (F-18 FDG PET/CT) related to primary tonsillar lymphoma are seldom.
      A 59-year-old man suffered from painful swelling of the bilateral tonsil. Biopsy
      diagnosed diffuse large B-cell lymphoma.
    explanation: The diagnosis of diffuse large B-cell lymphoma in the tonsils was
      confirmed through biopsy, supporting the necessity of biopsy for diagnosing
      primary tonsillar lymphoma.
  - reference: PMID:38742359
    supports: SUPPORT
    snippet: The clinical, pathological and ultrasonic data of nine patients with
      tonsillar lymphoma confirmed by pathology at Tianjin Medical University Cancer
      Institute and Hospital during June 2015 and June 2022 were analyzed retrospectively,
      and the characteristics of their ultrasonic images were summarized.
    explanation: The study confirms the diagnosis of tonsillar lymphoma through pathological
      examination, indicating the necessity of biopsy for confirmation.
- name: Imaging Studies
  notes: CT, MRI, or PET scans to evaluate the extent of disease and involvement of
    surrounding structures and distant sites.
  evidence:
  - reference: PMID:11338097
    supports: SUPPORT
    snippet: The clinical records and MR images of eight patients with primary NHL
      of the palatine tonsil were reviewed. Patients had a short duration of symptoms
      (mean 1 month). Systemic symptoms (fever, weight loss or night sweats) occurred
      in two patients. Tumours were round or lobulated and ranged in size from 30
      mm to 70 mm.
    explanation: The study describes the use of MRI to evaluate primary non-Hodgkin&#39;s
      lymphoma of the palatine tonsil, supporting the use of imaging studies to evaluate
      the extent of disease.
  - reference: PMID:20422687
    supports: SUPPORT
    snippet: Using a retrospective approach, the aim of this study was to confirm
      the previously described value of fluorine-18-fluorodeoxyglucose positron emission
      tomography/computed tomography ((18)F-FDG-PET/CT) in patients with primary extranodal
      lymphoma of the head and neck region.
    explanation: The study confirms the value of PET/CT in staging primary extranodal
      lymphoma of the head and neck, which includes tonsillar lymphoma.
  - reference: PMID:34600539
    supports: SUPPORT
    snippet: Primary tonsil diffuse large B cell lymphoma (PT-DLBCL) is an uncommon
      disease entity. The role of radiation therapy (RT) in PT-DLBCL is debatable
      in both the pre- and post-rituximab era. The purpose of this study was to evaluate
      the treatment outcome and establish a prognostic model in PT-DLBCL based on
      the Surveillance, Epidemiology, and End Results (SEER) database.
    explanation: The study discusses the evaluation and treatment of primary tonsil
      diffuse large B cell lymphoma, indicating the use of imaging studies to assess
      the extent of the disease.
- name: Blood Tests
  notes: CBC, LDH levels, and other markers for evaluating overall health and disease
    involvement.
  evidence:
  - reference: PMID:20440503
    supports: NO_EVIDENCE
    snippet: The present study aimed to define the natural history, World Health Organization
      (WHO) classification, prognostic factors, and treatment outcome of 87 patients
      with primary lymphoma of the palatine tonsil and literature review and analysis.
    explanation: The study focuses on the classification, prognostic factors, and
      treatment outcomes of primary tonsillar lymphoma but does not mention the use
      of blood tests such as CBC or LDH levels for evaluating overall health and disease
      involvement.
  - reference: PMID:28876549
    supports: PARTIAL
    snippet: In the BMI group, platelets in peripheral blood (PLT) and megakaryocyte
      count in bone marrow (MgK) were significantly lower than those in the non-BMI
      group... The rate of peripheral blood involvement by malignant lymphoma (PBI),
      red blood cell distribution width (RDW), D-dimer (DD), soluble interleukin-2
      receptor (sIL2R), aspartate aminotransferase (AST), and lactate dehydrogenase
      (LDH) was significantly higher in the BMI group than in the non-BMI group.
    explanation: This study indicates that certain blood markers, including LDH, are
      elevated in cases of bone marrow involvement by malignant lymphoma, which may
      relate to primary tonsillar lymphoma. However, it does not specifically address
      primary tonsillar lymphoma.
  - reference: PMID:6931618
    supports: PARTIAL
    snippet: Serum total lactic dehydrogenase (LDH) levels were examined in 42 patients
      with acute leukemia, 9 patients with chronic myeloid leukemia, 6 of them in
      blastic crisis, and 53 patients with lymphoma and other lymphoproliferative
      disorders.
    explanation: The study shows that LDH levels are elevated in patients with lymphoma,
      which could be relevant for primary tonsillar lymphoma. However, it does not
      specifically mention primary tonsillar lymphoma or the use of CBC.
  - reference: PMID:18479855
    supports: PARTIAL
    snippet: Serum levels of LDH, sIL-2r, age and lymph node size in the ML group
      were significantly higher than in the benign group.
    explanation: The study indicates that elevated LDH levels could be indicative
      of malignant lymphoma, which may include primary tonsillar lymphoma. However,
      it does not specifically address primary tonsillar lymphoma or the use of CBC.
treatments:
- name: Chemotherapy
  description: Systemic treatment aimed at eradicating lymphoma cells, often using
    CHOP regimen (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone).
  evidence:
  - reference: PMID:10592134
    supports: SUPPORT
    snippet: We report six cases of primary tonsillar lymphoma with a median patient
      age of 42 years. There were two lymphoma cases with diffuse large cells, two
      cases with mixed small and large cells, one with small cells and one indeterminate.
      They were treated with six cycles of chemotherapy and cervical radiotherapy.
      All patients achieved durable complete remission.
    explanation: The study discusses the use of chemotherapy, including CHOP regimen,
      for the treatment of primary tonsillar lymphoma, which supports the statement.
  - reference: PMID:31894937
    supports: SUPPORT
    snippet: Non-Hodgkin lymphoma is treated with CHOP (cyclophosphamide, doxorubicin,
      vincristine, and prednisone) with or without rituximab (R-CHOP)... Chemotherapy
      treatment plans differ between the main subtypes of lymphoma.
    explanation: The study mentions the use of CHOP regimen for treating non-Hodgkin
      lymphoma, which includes primary tonsillar lymphoma.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
- name: Radiation Therapy
  description: Targeted radiation to the tonsil and surrounding structures to control
    local disease.
  evidence:
  - reference: PMID:8189757
    supports: NO_EVIDENCE
    snippet: &#39;CONCLUSION: This study substantiates the effectiveness of radiation
      therapy in patients with squamous cell carcinoma of the tonsil.&#39;
    explanation: The study is focused on squamous cell carcinoma of the tonsil, not
      primary tonsillar lymphoma.
  - reference: PMID:20706049
    supports: NO_EVIDENCE
    snippet: Non-Hodgkin lymphomas quite often present in the head and neck but primary
      tonsillar lymphomas of extranodal non-Hodgkin lymphomas are far less than 1%
      of head and neck malignancies.
    explanation: This reference mentions primary tonsillar lymphoma but does not provide
      specific evidence on the effectiveness of targeted radiation therapy for local
      disease control.
  - reference: PMID:23790512
    supports: NO_EVIDENCE
    snippet: Radiation therapy (RT) is the most effective single modality for local
      control of Hodgkin lymphoma (HL) and an important component of therapy for many
      patients.
    explanation: This reference discusses radiation therapy for Hodgkin lymphoma,
      not primary tonsillar lymphoma.
  - reference: PMID:10592134
    supports: NO_EVIDENCE
    snippet: There have been many reports that favor aggressive systemic treatment
      with chemotherapy and radiotherapy, even for well-localized lymphomas, avoiding
      the need for tonsillectomy of the normal tonsil.
    explanation: The reference discusses a combination of chemotherapy and radiotherapy
      for primary tonsillar lymphoma but does not provide specific details on targeted
      radiation therapy for local disease control.
  - reference: PMID:38742359
    supports: NO_EVIDENCE
    snippet: The clinical, pathological and ultrasonic data of nine patients with
      tonsillar lymphoma confirmed by pathology at Tianjin Medical University Cancer
      Institute and Hospital during June 2015 and June 2022 were analyzed retrospectively.
    explanation: This reference focuses on the ultrasonic features of tonsillar lymphoma
      and does not provide evidence on targeted radiation therapy for local disease
      control.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
- name: Targeted Therapy
  description: Use of drugs like rituximab for B-cell lymphomas.
  evidence:
  - reference: PMID:15252219
    supports: SUPPORT
    snippet: Rituximab, a monoclonal antibody directed against the B cell-specific
      protein CD20, has revolutionized lymphoma treatment by providing a highly effective
      form of therapy with relatively mild toxic side effects.
    explanation: This reference supports the use of rituximab as a targeted therapy
      for B-cell lymphomas.
  - reference: PMID:10592134
    supports: NO_EVIDENCE
    snippet: We report six cases of primary tonsillar lymphoma with a median patient
      age of 42 years. ... They were treated with six cycles of chemotherapy and cervical
      radiotherapy.
    explanation: This reference discusses chemotherapy and radiotherapy for primary
      tonsillar lymphoma but does not mention rituximab.
  - reference: PMID:18381106
    supports: SUPPORT
    snippet: Iodine 131-tositumomab and ibritumomab tiuxetan, radioimmunoconjugates
      that target the CD20 antigen, have been approved in the United States for use
      in relapsed or refractory, indolent, and transformed B-cell lymphomas.
    explanation: This reference supports the use of targeted therapies, specifically
      mentioning CD20-targeting agents for B-cell lymphomas, which includes rituximab.
  - reference: PMID:30709635
    supports: PARTIAL
    snippet: While the innovations in terms of B-cell lymphomas are certainly less
      significant, mention must also be made of the value of rituximab combined with
      polychemotherapy (CHOP) and of lenalidomide (as second-line therapy) in primary
      cutaneous diffuse large B-cell lymphoma, leg type.
    explanation: This reference mentions rituximab as part of the treatment for a
      specific type of B-cell lymphoma, but not specifically for primary tonsillar
      lymphoma.
  - reference: PMID:32755987
    supports: SUPPORT
    snippet: The addition of rituximab, a monoclonal antibody against CD20, to upfront
      therapy has improved survival outcomes for high-risk patients and may allow
      decreased total chemotherapy in those with low-risk disease.
    explanation: This reference supports the use of rituximab as a targeted therapy
      for B-cell lymphomas.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Stem Cell Transplant
  description: Considered in certain cases where high-dose chemotherapy is followed
    by infusion of healthy stem cells to restore bone marrow function.
  evidence:
  - reference: PMID:32725379
    supports: SUPPORT
    snippet: Based on high rates of long-term remission, our first choice for consolidation
      therapy is high-dose chemotherapy with autologous stem-cell transplant using
      thiotepa, busulfan, and cyclophosphamide as a myeloablative regimen, with a
      curative intent.
    explanation: The reference discusses the use of high-dose chemotherapy followed
      by stem-cell transplant as a consolidation therapy, which aligns with the statement
      about primary tonsillar lymphoma.
  - reference: PMID:20359581
    supports: SUPPORT
    snippet: Results of conventional or high-dose chemotherapy for peripheral T-cell
      lymphoma (PTCL) are unsatisfactory, leaving a potential role for autologous
      or allogeneic stem cell transplantation.
    explanation: The reference indicates that high-dose chemotherapy followed by stem
      cell transplantation is considered for certain types of lymphoma, supporting
      the statement.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
notes: Primary Tonsillar Lymphoma is a rare subtype of lymphoma that occurs in the
  tonsils and can spread to nearby and distant lymph nodes. Early symptoms often mimic
  other ENT conditions but require biopsy and imaging for accurate diagnosis. Treatment
  usually involves a combination of chemotherapy, radiation, and potentially targeted
  therapies to manage the disease and prevent recurrence.
disease_term:
  preferred_term: tonsillar lymphoma
  term:
    id: MONDO:0044884
    label: tonsillar lymphoma
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Primary_Tonsillar_Lymphoma.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>